A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects

NCT06159101 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

304

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Male Volunteers

Interventions

DRUG: HLX13
DRUG: CN-sourced ipilimumab
DRUG: EU-sourced ipilimumab group
DRUG: US-sourced ipilimumab group

Sponsor

Shanghai Henlius Biotech